Editorial Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2024; 30(23): 2959-2963
Published online Jun 21, 2024. doi: 10.3748/wjg.v30.i23.2959
Early colorectal cancer screening–no time to lose
Ying Wang, Zheng-Long Wu, Yi-Gang Wang, Xiao-Yuan Jia, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China
Ying Wang, Hui Wang, Department of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou 310018, Zhejiang Province, China
ORCID number: Yi-Gang Wang (0000-0003-4546-8179); Xiao-Yuan Jia (0000-0002-6297-6901).
Co-corresponding authors: Yi-Gang Wang and Hui Wang.
Author contributions: Wang Y performed the majority of the writing; Wu ZL and Wang H coordinated the writing of the paper; Jia XY and Wang YG contributed to the conception and design of the paper, literature review, critical revision and approval of the final version.
Supported by The Hangzhou Medical Health Science and Technology Project, No. B20220173; The Public Welfare Technology Project of Zhejiang Province, No. LGF21H160033; and Zhejiang Medical Technology Plan Project, No. 2021KY047.
Conflict-of-interest statement: Dr. Wang has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Wang, MD, Department of Oncology, Zhejiang Xiaoshan Hospital, No. 728 Yucai North Road, Xiaoshan District, Hangzhou 310018, China. wanghui19840106@126.com
Received: March 22, 2024
Revised: May 15, 2024
Accepted: May 27, 2024
Published online: June 21, 2024
Processing time: 90 Days and 23.3 Hours

Abstract

In this editorial, we comment on the article entitled “Stage at diagnosis of colorectal cancer through diagnostic route: Who should be screened?” by Agatsuma et al. Colorectal cancer (CRC) is emerging as an important health issue as its incidence continues to rise globally, adversely affecting the quality of life. Although the public has become more aware of CRC prevention, most patients lack screening awareness. Some poor lifestyle practices can lead to CRC and symptoms can appear in the early stages of CRC. However, due to the lack of awareness of the disease, most of the CRC patients are diagnosed already at an advanced stage and have a poor prognosis.

Key Words: Colorectal cancer; The immunochemical fecal occult blood test; Diagnostic route; Cancer screening; Stage at diagnosis

Core Tip: Briefly summarises the factors that contribute to colorectal cancer (CRC) and the early symptoms. The use of the immunochemical fecal occult blood test in different countries is explored as well as the importance of screening at an early stage. Highlighting the critical role of early screening in CRC treatment, this editorial carefully blends social context and scientific insights to reveal the dynamic landscape of this evolving field.



INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer worldwide, and its occurrence and progression are largely attributed to genetic instability of key mutated genes[1]. Although CRC patients undergo surgery and chemotherapy, the side effects and recurrence rate remain high. Patients with advanced CRC usually have poor outcomes. Therefore, in order to improve prognosis, early treatment is necessary, which will increase patient survival[2-5]. In order to disseminate knowledge about CRC screening, public health institutions are also trying to promote the importance of CRC screening. Studies have found that approximately 30%-50% of the eligible population do not receive early screening for CRC. In addition, more than 70% of CRC cases are detected through non-screening routes[6,7].

Early symptoms of CRC are not obvious, thus it is often found only in the late stage in the clinic. In addition, CRC is also a challenging disease, and its pathogenesis is unclear. However, compared to other cancers, CRC is an easily preventable cancer. Due to no obvious symptoms in the early stages of CRC development, it is essential to develop early detection techniques.

However, there are shortcomings in traditional screening methods, and many people who are eligible for screening have not been screened[8]. This paper describes CRC diagnosed earlier in hospitals, and the methods we recommended for early CRC screening.

EARLY-ONSET CRC RISK FACTORS AND SYMPTOMS

CRC is associated with a number of risk factors. In Western countries, there is evidence that these risk factors are associated with lifestyles such as smoking, overweight, excessive alcohol consumption, consumption of red meat and processed meat, low calcium and dietary fiber intake and inadequate consumption of fruit and vegetables[9,10]. Recent work from the Nurses’ Health Study found prolonged sedentary television viewing, a surrogate for an inactive lifestyle, was associated with an increased risk of early-onset CRC, particularly rectal cancer[11].

According to surveys and statistics, rectal bleeding is the most prevalent danger sign in patients with early CRC[12]. In addition, pain, changes in bowel habits such as constipation, diarrhea, unexplained weight loss, and anemia are also observed[13-16]. Previous studies have found that patients with early CRC, compared to patients with advanced CRC and control populations, present with abdominal pain, rectal pain, changes in bowel habits, rectal bleeding and weight loss. Many of these symptoms occur in the early stage of CRC. Similarly, studies have found that patients with early-onset CRC present with abdominal pain, rectal pain, changes in bowel habits, rectal bleeding, and weight loss suggestive of an increased risk of early-onset CRC when compared to patients with late-onset CRC and control populations[17].

Although early CRC can result in symptoms, the current state of treatment is not encouraging. It has been shown that patients with early stage CRC take an average of six months from onset to diagnosis[15,18-20]. There are several reasons why it takes so long to confirm the diagnosis. Firstly, patients do not realize that they are going to develop cancer, and there is very little awareness of basic care and healthcare protection. Secondly, some patients mistake the common conditions mentioned earlier for hemorrhoids, for example when bleeding from the rectum[21,22]. Although the patient is unaware, it has been established that, at the time of diagnosis, these symptoms usually predict that colon cancer is already at an advanced stage and has a poor prognosis. Therefore, the adoption and implementation of standardized diagnostic tests is extremely important for the early diagnosis of CRC.

EARLY SCREENING OF CRC AND THE IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST

CRC is a highly malignant tumor, its clinical manifestations and prognosis are closely related. Early screening and early detection can greatly improve the prognosis. As the incidence of CRC increases year by year, the United States government is also actively encouraging individuals to participate in CRC screening, but unfortunately, more than 70% of eligible people are not screened[23].

The incidence of CRC has increased significantly according to annual CRC registries, and there are a growing number of high-risk and screening groups. Early screening for CRC should not be delayed. In addition, there has been a report summarising current CRC screening guidelines and highlighting future blood-based and imaging-based screening programmes[24]. To date, although some progress has been made in CRC screening, there is still a considerable number of people who are not effectively screened for CRC, and there is a lack of effective CRC screening methods and follow-up instructions[8]. Effective and necessary recommendations for CRC screening or follow-up are also needed for patients who are not adhering to treatment. CRC screening is a labor-intensive, material-intensive process, and tailoring information to each patient is costly[23,25-28]. However, screening and treatment are essential in the early stages of the disease, and the cost is greatly reduced compared to the cost of late treatment.

A recent issue of the World Journal of Gastroenterology published an interesting paper entitled “Stage at diagnosis of colorectal cancer through diagnostic route: Who should be screened?”[8]. This study focused on the fact that screening reduced CRC deaths in Japan. CRC treatments rely heavily on the efficacy of early screening as well as the detection of CRC at an earlier and more appropriate time plus timely removal of the lesion. Japan also provides new technical support for the early screening of CRC and precancerous lesions, as well as a theoretical basis for the early diagnosis and treatment of CRC[29]. The research data for this article were from two local hospitals. Both hospitals are among the top hospitals in Japan for treating CRC cases and are designated as Cancer Care Hospitals. They treat many CRC cases, including many CRC patients in cancer care homes. Patients registered at both institutions were enrolled in the study. The conclusion drawn on the basis of these two hospitals is therefore informative.

This article used cancer registries from two Japanese facilities to clarify the stage at diagnosis in three groups: Cancer screening, follow-up (patients detected during follow-up for other comorbidities), and symptomatic patients with some concomitant symptoms of bowel disease[8]. Symptomatic patients who show some unusual clinical manifestations are seen in hospital and are more inclined to undergo imaging and colonoscopy. It also confirms previous research that patients with some chronic diseases can be treated earlier due to their medical history[30,31].

In addition, this article highlights the significance of the local policy and medical environment in Japan for early CRC screening[8]. Japan's well-developed healthcare and universal insurance systems enable residents to make unlimited use of health resources[32] and to make screening a priority. Therefore, when a patient arrives at the hospital, having a quick test performed improves their chances of being diagnosed quickly. In addition, the advanced local healthcare infrastructure allows the use of advanced diagnostic techniques such as colonoscopy and computed tomography (CT) to help detect CRC patients earlier.

Last but not least, the immunochemical fecal occult blood test (iFOBT) is mentioned in the article[8]. The FOBT is a fairly popular method for CRC screening, especially for patients who are reluctant to undergo invasive tests such as CT colonography and colonoscopy. The FOBT consists of two tests: Chemo (gFOBT) and iFOBT. These methods are widely used in the United States and provide patients with an excellent option for early screening of CRC[33]. The use of iFOBT reduces the false-positive rate of CRC compared to the use of gFOBT (piaq-based fecal occult blood test) for CRC screening[34]. The iFOBT is also widely used in Australia. Studies have also found that 2-yearly iFOBT screening is not only beneficial to health but also cost-effective[35]. In Japan, as a result of the use of iFOBT, CRC incidence has been reduced by 10%[36] and CRC mortality by 62%[37]. An analysis of test characteristics showed that the iFOBT had a combined sensitivity of 79% for the detection of CRC[38]. The predictive value of iFOBT is used for the development of colorectal progressive adenomas in the clinical setting. In China, CRC is more likely to occur in people with advanced age, those who smoke, have diabetes mellitus, and who previously underwent a cholecystectomy; thus, attention should be paid to these groups, and use of the iFOBT has diagnostic significance for the development of adenoma in progressive stages[39]. The iFOBT is recommended for annual CRC screening because of its superior detection properties and its convenience compared with colonoscopy[40].

CONCLUSION

With the progress of research, the incidence and mortality of CRC are decreasing year by year[41]. However, its pathogenic mechanism is still unclear. The study in Japan underscores how early screening can effectively reduce the average risk of developing the disease partly due to early diagnosis and timely treatment[42]. The article also pointed out the necessity of implementing the iFOBT strategy. The health sector advocates active participation in patient health education and offers screening advice tailored to individual patient needs. This reduces pain and related complications in patients with advanced cancer. We hope that early screening, early detection and effective intervention will reduce mortality from CRC.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade A

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade A

P-Reviewer: Li CY, United States S-Editor: Fan JR L-Editor: A P-Editor: Zhao YQ

References
1.  National Health Commission of the People′s Republic of China; Chinese Society of Oncology. [Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer (2023 edition)]. Zhonghua Wai Ke Za Zhi. 2023;61:617-644.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 3]  [Reference Citation Analysis (0)]
2.  Kubisch CH, Crispin A, Mansmann U, Göke B, Kolligs FT. Screening for Colorectal Cancer Is Associated With Lower Disease Stage: A Population-Based Study. Clin Gastroenterol Hepatol. 2016;14:1612-1618.e3.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 39]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
3.  Friedrich K, Grüter L, Gotthardt D, Eisenbach C, Stremmel W, Scholl SG, Rex DK, Sieg A. Survival in patients with colorectal cancer diagnosed by screening colonoscopy. Gastrointest Endosc. 2015;82:133-137.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 15]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
4.  Araghi M, Arnold M, Rutherford MJ, Guren MG, Cabasag CJ, Bardot A, Ferlay J, Tervonen H, Shack L, Woods RR, Saint-Jacques N, De P, McClure C, Engholm G, Gavin AT, Morgan E, Walsh PM, Jackson C, Porter G, Møller B, Bucher O, Eden M, O'Connell DL, Bray F, Soerjomataram I. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut. 2021;70:114-126.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 69]  [Cited by in F6Publishing: 74]  [Article Influence: 24.7]  [Reference Citation Analysis (0)]
5.  Ariyoshi M, Nishikitani M, Tsurugano S, Inoue M, Yano E. The Association of Health Status and Employment Status for each Occupation: Results from a Comprehensive Survey of Living Conditions in Japan1. Jpn Psychol Res. 2023;65:201-214.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
6.  Sabatino SA, Thompson TD, White MC, Shapiro JA, Clarke TC, Croswell JM, Richardson LC. Cancer Screening Test Use-U.S., 2019. Am J Prev Med. 2022;63:431-439.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 15]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
7.  Weller D, Menon U, Zalounina Falborg A, Jensen H, Barisic A, Knudsen AK, Bergin RJ, Brewster DH, Cairnduff V, Gavin AT, Grunfeld E, Harland E, Lambe M, Law RJ, Lin Y, Malmberg M, Turner D, Neal RD, White V, Harrison S, Reguilon I; ICBP Module 4 Working Group, Vedsted P. Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). BMJ Open. 2018;8:e023870.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 43]  [Article Influence: 7.2]  [Reference Citation Analysis (0)]
8.  Agatsuma N, Utsumi T, Nishikawa Y, Horimatsu T, Seta T, Yamashita Y, Tanaka Y, Inoue T, Nakanishi Y, Shimizu T, Ohno M, Fukushima A, Nakayama T, Seno H. Stage at diagnosis of colorectal cancer through diagnostic route: Who should be screened? World J Gastroenterol. 2024;30:1368-1376.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (6)]
9.  Moore HG. Colorectal cancer: what should patients and families be told to lower the risk of colorectal cancer? Surg Oncol Clin N Am. 2010;19:693-710.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 14]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
10.  Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 902]  [Cited by in F6Publishing: 907]  [Article Influence: 151.2]  [Reference Citation Analysis (2)]
11.  Nguyen LH, Liu PH, Zheng X, Keum N, Zong X, Li X, Wu K, Fuchs CS, Ogino S, Ng K, Willett WC, Chan AT, Giovannucci EL, Cao Y. Sedentary Behaviors, TV Viewing Time, and Risk of Young-Onset Colorectal Cancer. JNCI Cancer Spectr. 2018;2:pky073.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 72]  [Cited by in F6Publishing: 119]  [Article Influence: 23.8]  [Reference Citation Analysis (0)]
12.  Myers EA, Feingold DL, Forde KA, Arnell T, Jang JH, Whelan RL. Colorectal cancer in patients under 50 years of age: a retrospective analysis of two institutions' experience. World J Gastroenterol. 2013;19:5651-5657.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 104]  [Cited by in F6Publishing: 120]  [Article Influence: 10.9]  [Reference Citation Analysis (0)]
13.  Silva ACB, Vicentini MFB, Mendoza EZ, Fujiki FK, da Fonseca LG, Braghiroli MIFM, Hoff PM. Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center. Curr Probl Cancer. 2019;43:477-486.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
14.  Frostberg E, Rahr HB. Clinical characteristics and a rising incidence of early-onset colorectal cancer in a nationwide cohort of 521 patients aged 18-40 years. Cancer Epidemiol. 2020;66:101704.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 10]  [Cited by in F6Publishing: 10]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
15.  Olivo R, Ratnayake S. Colorectal cancer in young patients: a retrospective cohort study in a single institution. ANZ J Surg. 2019;89:905-907.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 11]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
16.  Dharwadkar P, Greenan G, Singal AG, Murphy CC. Is Colorectal Cancer in Patients Younger Than 50 Years of Age the Same Disease as in Older Patients? Clin Gastroenterol Hepatol. 2021;19:192-194.e3.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 16]  [Article Influence: 5.3]  [Reference Citation Analysis (0)]
17.  Syed AR, Thakkar P, Horne ZD, Abdul-Baki H, Kochhar G, Farah K, Thakkar S. Old vs new: Risk factors predicting early onset colorectal cancer. World J Gastrointest Oncol. 2019;11:1011-1020.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 42]  [Cited by in F6Publishing: 53]  [Article Influence: 10.6]  [Reference Citation Analysis (0)]
18.  Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109-131.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 196]  [Cited by in F6Publishing: 368]  [Article Influence: 61.3]  [Reference Citation Analysis (0)]
19.  Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced-Stage Colorectal Cancer in Persons Younger Than 50 Years Not Associated With Longer Duration of Symptoms or Time to Diagnosis. Clin Gastroenterol Hepatol. 2017;15:728-737.e3.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 111]  [Cited by in F6Publishing: 181]  [Article Influence: 25.9]  [Reference Citation Analysis (0)]
20.  Scott RB, Rangel LE, Osler TM, Hyman NH. Rectal cancer in patients under the age of 50 years: the delayed diagnosis. Am J Surg. 2016;211:1014-1018.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 64]  [Article Influence: 7.1]  [Reference Citation Analysis (0)]
21.  O'Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187:343-348.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 202]  [Cited by in F6Publishing: 241]  [Article Influence: 12.1]  [Reference Citation Analysis (0)]
22.  Patel SG, Ahnen DJ. Colorectal Cancer in the Young. Curr Gastroenterol Rep. 2018;20:15.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 89]  [Cited by in F6Publishing: 124]  [Article Influence: 20.7]  [Reference Citation Analysis (0)]
23.  Hirai K, Ishikawa Y, Fukuyoshi J, Yonekura A, Harada K, Shibuya D, Yamamoto S, Mizota Y, Hamashima C, Saito H. Tailored message interventions versus typical messages for increasing participation in colorectal cancer screening among a non-adherent population: A randomized controlled trial. BMC Public Health. 2016;16:431.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 19]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
24.  Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022;19:521-531.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 153]  [Article Influence: 76.5]  [Reference Citation Analysis (0)]
25.  Kapinos KA, Halm EA, Murphy CC, Santini NO, Loewen AC, Skinner CS, Singal AG. Cost Effectiveness of Mailed Outreach Programs for Colorectal Cancer Screening: Analysis of a Pragmatic, Randomized Trial. Clin Gastroenterol Hepatol. 2022;20:2383-2392.e4.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 4]  [Reference Citation Analysis (0)]
26.  Hamashima C, Sano H. Association between age factors and strategies for promoting participation in gastric and colorectal cancer screenings. BMC Cancer. 2018;18:345.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 6]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
27.  Sekiguchi M, Igarashi A, Matsuda T, Matsumoto M, Sakamoto T, Nakajima T, Kakugawa Y, Yamamoto S, Saito H, Saito Y. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data. Jpn J Clin Oncol. 2016;46:116-125.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 9]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
28.  Steinwachs D, Allen JD, Barlow WE, Duncan RP, Egede LE, Friedman LS, Keating NL, Kim P, Lave JR, Laveist TA, Ness RB, Optican RJ, Virnig BA. National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening. Ann Intern Med. 2010;152:663-667.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 65]  [Cited by in F6Publishing: 72]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
29.  Winawer SJ. The history of colorectal cancer screening: a personal perspective. Dig Dis Sci. 2015;60:596-608.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 51]  [Cited by in F6Publishing: 48]  [Article Influence: 5.3]  [Reference Citation Analysis (1)]
30.  Zafar SY, Abernethy AP, Abbott DH, Grambow SC, Marcello JE, Herndon JE 2nd, Rowe KL, Kolimaga JT, Zullig LL, Patwardhan MB, Provenzale DT. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer. 2008;8:345.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 37]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
31.  Taneja S, Mandayam S, Kayani ZZ, Kuo YF, Shahinian VB. Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population. Clin J Am Soc Nephrol. 2007;2:1008-1013.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 24]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
32.  Sugiyama K, Oshio T, Kuwahara S, Kimura H. Association between having a primary care physician and health behavioral intention in Japan: results from a nationwide survey. BMC Prim Care. 2023;24:280.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
33.  Bechtold ML, Ashraf I, Nguyen DL. A Clinician's Guide to Fecal Occult Blood Testing for Colorectal Cancer. South Med J. 2016;109:248-255.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 6]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
34.  Ransohoff DF. What is the role of iFOBT in screening for colorectal cancer? Gut. 2007;56:1343-1344.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 7]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
35.  Lew JB, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, He E, Grogan P, Caruana M, Sarfati D, Greuter MJE, Coupé VMH, Canfell K. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. Int J Cancer. 2018;143:269-282.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 21]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
36.  Giorgi Rossi P, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F, Mangone L, Pezzarossi A, Roncaglia F, Campari C, Sassatelli R, Sacchero R, Sereni G, Paterlini L, Zappa M. Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy. Am J Gastroenterol. 2015;110:1359-1366.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 92]  [Cited by in F6Publishing: 104]  [Article Influence: 11.6]  [Reference Citation Analysis (0)]
37.  Chiu HM, Chen SL, Yen AM, Chiu SY, Fann JC, Lee YC, Pan SL, Wu MS, Liao CS, Chen HH, Koong SL, Chiou ST. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer. 2015;121:3221-3229.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 158]  [Cited by in F6Publishing: 188]  [Article Influence: 20.9]  [Reference Citation Analysis (0)]
38.  Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 389]  [Cited by in F6Publishing: 450]  [Article Influence: 45.0]  [Reference Citation Analysis (0)]
39.  Wang X, Zhang JY, Zheng ZQ, Wang T, Piao MY, Liu H, Liu J, Liu WT. [Value of combined detection of IFOBT, tumor markers, and inflammatory markers in predicting occurrence of advanced colorectal adenoma]. Shijie Huaren Xiaohua Zazhi. 2021;29:347-355.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
40.  Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastrointest Endosc. 2017;85:2-21.e3.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 44]  [Cited by in F6Publishing: 43]  [Article Influence: 6.1]  [Reference Citation Analysis (0)]
41.  Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1390]  [Cited by in F6Publishing: 1474]  [Article Influence: 105.3]  [Reference Citation Analysis (1)]
42.  Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687-696.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1952]  [Cited by in F6Publishing: 2172]  [Article Influence: 181.0]  [Reference Citation Analysis (1)]